Therapeutic Products

APO-1 (APOSECTM): Injectable formulation for the improvement of cardiac function in chronic myocardial ischemia
Discussions are underway for the design of a clinical program in this indication together with a manufacturer of catheter devices suitable for direct myocardial injection of APO-1 (APOSECTM).

APO-2 (APOSECTM): Topical formulation for the treatment of diabetic foot ulcers and other chronic wounds
Aposcience AG will initiate a program to demonstrate safety and efficacy in this important indication with very large unmet medical need. The program consists of a phase I study in healthy volunteers, followed by a phase IIa study in a selected patient population. This program is designed to translate the extremely promising data from animal models into clinical practice.

Marsyas I, a prospective, single-center, randomized, double-blinded, placebo controlled, dose finding clinical phase I study in the indication wound healing ( Identifier: NCT02284360) was initiated on 23 October 2014 at the Department of Clinical Pharmacology of the Medical University of Vienna. The study was completed on 5 February 2016 (date of study Report). A Synopsis can be found here: Study Report - Synopsis PDF Download

Marsyas II, a randomized, placebo-controlled, double-blind study to evaluate safety and dosedependent clinical efficacy of APO-2 at three different doses in patients with diabetic foot ulce  (EudraCT number: 2018-001653-27, Identifier: NCT04277598) was initiated in October 202. More information can be found Öffnet internen Link im aktuellen Fensterhere and at Öffnet externen Link in neuem

Latest News

Approval of DSMB for Lead In-Phase and Go-Ahead for MARSYAS II Main Study



Approval for clinical phase II study in DFU by German health agency PEI